Catalyst Wire Dossier Catalyst Wire Dossier

BIIB093 (Glibenclamide)

glibenclamide · Remedy Pharmaceuticals, Inc
Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for BIIB093 (Glibenclamide), covering 2024-01-09 to 2024-01-09. Get the full timeline:

Most recent: Clinical Trial Update: Phase 3 Study to Evaluate the Efficacy and Safety of Intravenous BIIB093 (Glibenclamide) for Severe Cerebral Edema Following Large Hemispheric Infarction [Phase 3]

See pricing